Multicenter, double-blind, randomized, placebo-controlled, 5-period, 5-treatment crossover, dose-finding study to evaluate the efficacy and safety of oral administration of ACT-078573 [almorexant] in elderly subjects with chronic primary insomnia.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Almorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 14 Nov 2012 Actual end date changed from Aug 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 22 Dec 2008 Status changed from active, no longer recruiting to completed.
- 06 Mar 2008 New trial record.